Clinical trials · San Francisco, CA
Neuroendocrine Tumors clinical trials in San Francisco
We’re tracking 12 recruiting neuroendocrine tumors studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT07129252RecruitingPhase 1/Phase 2
A study of CRN09682 for NET and other solid tumors
This trial tests a new drug called CRN09682 for people with neuroendocrine tumors (NETs) or other solid tumors that have grown despite treatment and show a specific marker on scans. The goal is to see if the drug is safe and works against these cancers.
San Francisco, CaliforniaAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
San Francisco, CaliforniaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
San Francisco, CaliforniaAges Any age - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
San Francisco, CaliforniaAges 18 years+ - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
San Francisco, CaliforniaAges 18 years+ - NCT06788938RecruitingPhase 2
Tarlatamab for advanced DLL3-positive tumors
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
San Francisco, CaliforniaAges 18 years+ - NCT05746208RecruitingPhase 2
Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
San Francisco, CaliforniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Emeryville, CaliforniaAges 18 years+ - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Emeryville, CaliforniaAges 18 years+ - NCT06943755RecruitingPhase 2/Phase 3
Zanzalintinib vs Everolimus for Neuroendocrine Tumors
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Vallejo, CaliforniaAges 18 years+ - NCT02174549RecruitingPhase 1/Phase 2
Testing a drug with liver artery treatment for liver-spread neuroendocrine cancer
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
Palo Alto, CaliforniaAges 20–99 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Stanford, CaliforniaAges 18–75
Hear when a new Neuroendocrine Tumors trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Neuroendocrine Tumors trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting neuroendocrine tumors studies listed above.
- University of California, San Francisco · 3 studies
- Bay Area Breast Surgeons Inc · 2 studies
- Bay Area Tumor Institute · 2 studies
- Contra Costa Regional Medical Center · 2 studies
- Epic Care Cyberknife Center · 2 studies
- Epic Care Partners in Cancer Care · 2 studies
- Epic Care-Dublin · 2 studies
- Alta Bates Summit Medical Center
What taking part in a neuroendocrine tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neuroendocrine tumors studies in California.
Common questions
- Are there neuroendocrine tumors clinical trials near San Francisco?
- Yes. We're currently tracking 12 recruiting neuroendocrine tumors studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neuroendocrine tumors study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neuroendocrine tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neuroendocrine tumors studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.